The FDA assessed the security and usefulness of atidarsagene autotemcel dependant on information from 37 young children who been given atidarsagene autotemcel in two single-arm, open-label clinical trials and in an expanded entry method.[seven] Children who obtained cure with atidarsagene autotemcel were being in comparison to untreated youngsters